^
Association details:
| Biomarker: | MYCN amplification + ALK F1174L |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The ALK/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma
Excerpt:
...xenografts harboring the de novo crizotinib- resistant ALK F1174L mutation exhibited unprecedented anti-tumor responses to single agent ALK inhibition therapy with PF-06463922…Table 1…
DOI:
10.1158/2159-8290.CD-15-1056
